SCHEMBL1192192

SCHEMBL1192192

CS(=O)(=O)NCc1cccc(-c2nc3c(N4CCOCC4)nc(Cl)nc3s2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 2/20 0.51
CHUK O15111 2/20 0.51
AURKB Q96GD4 2/20 0.47
PIK3CA P42336 6/20 0.39
PIK3CD O00329 4/20 0.39
PIK3CB P42338 3/20 0.39
PIK3CG P48736 3/20 0.39
MTOR P42345 5/20 0.39
LMNA P02545 3/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
TSHR P16473 2/20 0.38
MAPK1 P28482 2/20 0.38
RECQL P46063 1/20 0.38
USP2 O75604 1/20 0.38
HIF1A Q16665 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
AVPR1B P47901 1/20 0.37
CDK2 P24941 1/20 0.37
BTK Q06187 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1192758 0.85 PIK3CA (0.55) IKBKBCHUKPIK3CAPIK3CDPIK3CB
SCHEMBL1192980 0.85 CYP1A2 (0.54) PIK3CAPIK3CDPIK3CBPIK3CGMTOR
SCHEMBL1191823 0.84 IKBKB (0.52) IKBKBCHUKAURKBPIK3CAPIK3CD
SCHEMBL1192052 0.83 PIK3CA (0.49) PIK3CAPIK3CDPIK3CBPIK3CGMTOR
SCHEMBL1192149 0.81 PIK3CA (0.49) IKBKBCHUKAURKBPIK3CAPIK3CD
SCHEMBL4439757 0.81 MTOR (0.53) AURKBPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL1192582 0.81 MTOR (0.48) PIK3CAPIK3CDPIK3CBPIK3CGMTOR
SCHEMBL1191980 0.80 HSD17B10 (0.45) PIK3CALMNATSHRMAPK1USP2
SCHEMBL1192071 0.78 PIK3CA (0.50) PIK3CAPIK3CDPIK3CBPIK3CGMTOR
SCHEMBL1192386 0.78 MTOR (0.51) PIK3CAMTORBTKKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2207781-B1 THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2012-11-28 EP disclosed
US-8158626-B2 Thiazolopyrimidine PI3K inhibitor compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2012-04-17 US disclosed
US-20110112085-A1 THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2011-05-12 US disclosed
US-7893059-B2 Thiazolopyrimidine PI3K inhibitor compounds and methods of use GENENTECH, INC. (US) 2011-02-22 US disclosed
EP-2207781-A1 THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE Genentech, Inc. (US) 2010-07-21 EP disclosed
US-20090118275-A1 THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2009-05-07 US disclosed
WO-2009042607-A1 THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112085-A1 THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, PIK3CB IKBKB 80/4885CHUK 29/4885AURKB 288/4885
US-20090118275-A1 THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE PIK3CA, PI4KB, PI4KA IKBKB 104/4885CHUK 65/4885AURKB 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.